Human medicines European public assessment report (EPAR): Hexyon, diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed), Date of authorisation: 17/04/2013, Date of refusal: 22/02/2013, Revision: 34, Status: Authorised

PRIME eligibility requests: 2026 deadlines for submission and timetable for assessment

Human medicines European public assessment report (EPAR): Hexacima, diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed), Date of authorisation: 17/04/2013, Date of refusal: 22/02/2013, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Tivicay, dolutegravir, Date of authorisation: 16/01/2014, Revision: 36, Status: Authorised

Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 37, Status: Authorised

Human medicines European public assessment report (EPAR): Imbruvica, ibrutinib, Date of authorisation: 21/10/2014, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR): Spravato, esketamine, Date of authorisation: 18/12/2019, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Arexvy, recombinant respiratory syncytial virus pre-fusion F protein, adjuvanted with AS01E, Date of authorisation: 06/06/2023, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Zonisamide Viatris (previously Zonisamide Mylan), zonisamide, Date of authorisation: 31/03/2016, Revision: 12, Status: Authorised

Management Board formally approves renewal of Executive Director’s mandate